Cullinan Therapeutics 旗下CLN-978在单靶点剂量高达30微克及初步多剂量方案中均展现良好安全性

美股速递
Jun 06

Cullinan Therapeutics公司研发的CLN-978,其安全性数据令人鼓舞。不仅在单靶点剂量高达30微克的水平上表现出良好的耐受性,初步的多剂量给药方案也显示出积极的安全特征。这一进展为后续的临床开发奠定了重要基础。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10